CytomX Therapeutics to Present at Upcoming September Investor Conferences

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] Upcoming Events - CytomX management will participate in several investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 4, 2025, with a fireside chat at 8:35 a.m. ET [2] - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with a formal presentation at 11:30 a.m. ET [2] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, with a fireside chat at 1:05 p.m. ET [2] - A live webcast of the presentations will be available on CytomX's website, and management will be available for one-on-one meetings with registered investors [2]